Article
Adenomatous Polyposis Coli Loss Controls Cell Cycle Regulators and Response to Paclitaxel
2020-11-01
Abstract excerpt
Adenomatous Polyposis Coli (APC) is lost in approximately 70% of sporadic breast cancers, with an inclination towards triple negative breast cancer (TNBC). TNBC is treated with traditional chemotherapy, such as paclitaxel (PTX); however, tumors often develop drug resistance. We previously created APC knockdown cells (APC shRNA1) using the human TNBC cells, MDA-MB-157, and showed that APC loss induces PTX resistanc...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 626fd069-0d3e-5def-9d8a-7d54d6c19bcb
- DOI
- 10.1101/2020.10.31.362608
